Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: 1a0cd3d9fafdc6c7dc78974a55eb6a65b0f79c4a
First added on: Feb 13, 2025